Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Relapse/Refractory Diffuse Large B-cell Lymphoma

NCT04856137 is registered in ClinicalTrials.gov with National Health Research Institutes, Taiwan as lead sponsor.

NCT NCT04856137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04856137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Relapse/Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
National Health Research Institutes, Taiwan
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 1, 2021
Completion date
December 31, 2028
Enrollment
74 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory diffuse large b-cell lymphoma